278 related articles for article (PubMed ID: 19874992)
21. Measurement of plasma ox-LDL and carotid IMT may represent useful markers for atherosclerosis and may represent potential targets for therapeutic interventions.
Savoiu G; Drăgan S; Cristescu C; Serban C; Noveanus L; Ionescu D; Nicola T; Duicu O; Raducan A; Voicu M
Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):397-401. PubMed ID: 21491821
[TBL] [Abstract][Full Text] [Related]
22. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.
Airan-Javia SL; Wolf RL; Wolfe ML; Tadesse M; Mohler E; Reilly MP
Am Heart J; 2009 Apr; 157(4):687.e1-8. PubMed ID: 19332196
[TBL] [Abstract][Full Text] [Related]
23. Effects of extended-release niacin on lipoprotein subclass distribution.
Morgan JM; Capuzzi DM; Baksh RI; Intenzo C; Carey CM; Reese D; Walker K
Am J Cardiol; 2003 Jun; 91(12):1432-6. PubMed ID: 12804729
[TBL] [Abstract][Full Text] [Related]
24. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
25. Lipid and transaminase concentrations after formulary conversion of Niaspan to Slo-Niacin.
Byrd C; Mowrey KA
Am J Health Syst Pharm; 2010 Dec; 67(23):2038-42. PubMed ID: 21098376
[TBL] [Abstract][Full Text] [Related]
26. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study.
Wiklund O; Hulthe J; Wikstrand J; Schmidt C; Olofsson SO; Bondjers G
Stroke; 2002 Feb; 33(2):572-7. PubMed ID: 11823672
[TBL] [Abstract][Full Text] [Related]
27. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis.
Labreuche J; Deplanque D; Touboul PJ; Bruckert E; Amarenco P
Atherosclerosis; 2010 Sep; 212(1):9-15. PubMed ID: 20457452
[TBL] [Abstract][Full Text] [Related]
28. A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography.
deGoma EM; Salavati A; Shinohara RT; Saboury B; Pollan L; Schoen M; Torigian DA; Mohler ER; Dunbar RL; Litt HI; Woo J; Rader DJ; Alavi A; Mehta NN
Acad Radiol; 2015 May; 22(5):600-9. PubMed ID: 25708866
[TBL] [Abstract][Full Text] [Related]
29. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
Morgan JM; Capuzzi DM; Guyton JR
Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
[TBL] [Abstract][Full Text] [Related]
30. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
31. Extended-release niacin for modifying the lipoprotein profile.
Guyton JR
Expert Opin Pharmacother; 2004 Jun; 5(6):1385-98. PubMed ID: 15163282
[TBL] [Abstract][Full Text] [Related]
32. Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia.
Kei A; Liberopoulos EN; Mikhailidis DP; Elisaf M
Int J Clin Pract; 2013 May; 67(5):412-9. PubMed ID: 23510018
[TBL] [Abstract][Full Text] [Related]
33. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial.
Karim R; Mack WJ; Lobo RA; Hwang J; Liu CR; Liu CH; Sevanian A; Hodis HN
Menopause; 2005; 12(4):366-73. PubMed ID: 16037751
[TBL] [Abstract][Full Text] [Related]
34. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
Hodis HN
J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
[TBL] [Abstract][Full Text] [Related]
35. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
[TBL] [Abstract][Full Text] [Related]
36. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).
Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
Int J Clin Pract; 2007 Nov; 61(11):1914-21. PubMed ID: 17935550
[TBL] [Abstract][Full Text] [Related]
37. The effect of cholesterol reduction with fluvastatin on aortic compliance, coronary calcification and carotid intimal-medial thickness: a pilot study.
Forbat SM; Naoumova RP; Sidhu PS; Neuwirth C; MacMahon M; Thompson GR; Underwood SR
J Cardiovasc Risk; 1998 Feb; 5(1):1-10. PubMed ID: 9816550
[TBL] [Abstract][Full Text] [Related]
38. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
Bays H; Shah A; Dong Q; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2011 Apr; 65(4):436-45. PubMed ID: 21401833
[TBL] [Abstract][Full Text] [Related]
39. [Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].
Safarova MS; Trukhacheva EP; Ezhov MV; Afanas'eva OI; Afanas'eva MI; Tripoten' MI; Liakishev AA; Pokrovskiĭ SN
Kardiologiia; 2011; 51(5):9-16. PubMed ID: 21649590
[TBL] [Abstract][Full Text] [Related]
40. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.
Kuvin JT; Dave DM; Sliney KA; Mooney P; Patel AR; Kimmelstiel CD; Karas RH
Am J Cardiol; 2006 Sep; 98(6):743-5. PubMed ID: 16950175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
